EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Engineering Cas9: next generation of genomic editors

Maxim A Kovalev, Artem I Davletshin, Dmitry S Karpov

Applied Microbiology and Biotechnology · 2024-12 · 108 (1)

DOI: 10.1007/s00253-024-13056-y ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Applied Microbiology and Biotechnology, online erschienen am 14.02.2024. Verfasst von Maxim A Kovalev und 2 weiteren Autor:innen. Beteiligte Einrichtung: Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str., 32, 119991, Moscow, Russia. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Genomics. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Cas9 endonuclease of the CRISPR/Cas type IIA system from Streptococcus pyogenes is the heart of genome editing technology that can be used to treat human genetic and viral diseases. Despite its large size and other drawbacks, S. pyogenes Cas9 remains the most widely used genome editor. A vast amount of research is aimed at improving Cas9 as a promising genetic therapy. Strategies include directed evolution of the Cas9 protein, rational design, and domain swapping. The first generation of Cas9 editors comes directly from the wild-type protein. The next generation is obtained by combining mutations from the first-generation variants, adding new mutations to them, or refining mutations. This review summarizes and discusses recent advances and ways in the creation of next-generation genomic editors derived from S. pyogenes Cas9. Key points • The next-generation Cas9-based editors are more active than in the first one. • PAM-relaxed variants of Cas9 are improved by increased specificity and activity. • Less mutagenic and immunogenic variants of Cas9 are created.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CRISPR-Cas SystemsGenomicsHumansMutagenesisMutationCRISPR-Associated Protein 9Streptococcus pyogenes

Stichwörter der Autor:innen

Altered PAM specificityCas9 immunopeptidesHigh-fidelity Cas9 variantsNext-generation genomic editorsStreptococcus pyogenes Cas9

Substanzen

CRISPR-Associated Protein 9

Autor:innen und Institutionen

  • Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str., 32, 119991, Moscow, Russia.
  • Department of Biology, Lomonosov Moscow State University, 119234, Moscow, Russia.
  • Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str., 32, 119991, Moscow, Russia. aleom@yandex.ru.
  • Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Vavilov Str., 32, 119991, Moscow, Russia. aleom@yandex.ru.

Förderung

  • Russian Science Foundation

Zitieren

APA

Kovalev, M. A., Davletshin, A. I., & Karpov, D. S. (2024). Engineering Cas9: next generation of genomic editors. Applied Microbiology and Biotechnology, 108(1). https://doi.org/10.1007/s00253-024-13056-y

Vancouver

Kovalev MA, Davletshin AI, Karpov DS. Engineering Cas9: next generation of genomic editors. Applied Microbiology and Biotechnology. 2024;108(1). doi:10.1007/s00253-024-13056-y

BibTeX
@article{Kovalev2024,
  author = {Kovalev, Maxim A and Davletshin, Artem I and Karpov, Dmitry S},
  title = {Engineering Cas9: next generation of genomic editors},
  journal = {Applied Microbiology and Biotechnology},
  year = {2024},
  volume = {108},
  number = {1},
  doi = {10.1007/s00253-024-13056-y}
}
Kostenlos starten →